

A'  
now abandoned which is a continuation-in-part of U.S. Serial No. 07/206,470 filed 14 June 1988  
and now abandoned which is a continuation-in-part of U.S. Serial No. 07/200,383 filed  
31 May 1988 and now abandoned. Also related is U.S. Serial No. 07/460,855, now patent  
No. 5,114,923 which is a continuation-in-part of U.S. Serial No. 07/299,880 listed above.

Please amend the claims as follows:

Please cancel claims 1-31 and substitute the following claims:

SUB C1  
32. Antibodies useful for immunoassays to detect a peptide which peptide comprises  
human or canine brain natriuretic peptide.

A2  
SUB B1  
33. The antibodies of claim 32 wherein said peptide is human brain natriuretic peptide  
of the formula:

R<sup>1</sup>-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-R<sup>2</sup>

wherein R<sup>1</sup> is selected from the group consisting of:

(H);  
Gly-;  
Ser-Gly-;  
Gly-Ser-Gly-;  
Gln-Gly-Ser-Gly-;  
Val-Gln-Gly-Ser-Gly-;  
Met-Val-Gln-Gly-Ser-Gly-;  
Lys-Met-Val-Gln-Gly-Ser-Gly-;  
Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-;  
Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-; and  
R<sup>3</sup>-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-

wherein R<sup>3</sup> is the 101 amino acid sequence shown for human BNP in Figure 8 at  
positions numbered 1-99 immediately upstream of the Ser residue to which R<sup>3</sup> is bound, or a  
C-terminal portion thereof; and

*SUB B2*  
R<sup>2</sup> is OH, NH<sub>2</sub> or NR<sub>2</sub> wherein each R is independently H or lower alkyl (1-4C); or R<sup>2</sup> is selected from the group consisting of:

Lys;  
Lys-Val;  
Lys-Val-Leu;  
Lys-Val-Leu-Arg;  
Lys-Val-Leu-Arg-Arg; and  
Lys-Val-Leu-Arg-Arg-His, or  
the C-terminal amides thereof.

*Ag cont'd*  
*SUB B3*  
34. The antibodies of claim 33 wherein the peptide is of the formula:  
Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His,  
or a C-terminal amide thereof.

*Ag cont'd*  
35. The antibodies of claim 33 wherein, in said human brain natriuretic peptide, R<sup>3</sup> is H and R<sup>2</sup> is OH or NH<sub>2</sub>.

*Ag cont'd*  
36. The antibodies of claim 33 wherein, in said human brain natriuretic peptide, R<sup>1</sup> is H and R<sup>2</sup> is OH or NH<sub>2</sub>.

*SUB B4*  
37. The antibodies of claim 32 wherein said peptide is canine natriuretic peptide of the formula:

R<sup>1</sup>-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R<sup>2</sup>  
wherein R<sup>1</sup> is selected from the group consisting of:

(H);  
Gly-;  
Ser-Gly-;  
Lys-Ser-Gly-;  
His-Lys-Ser-Gly-;  
Met-His-Lys-Ser-Gly-;

Met-Met-His-Lys-Ser-Gly-;  
Lys-Met-Met-His-Lys-Ser-Gly-;  
Pro-Lys-Met-Met-His-Lys-Ser-Gly-; and  
R<sup>3</sup>-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-;

wherein R<sup>3</sup> is the 100 amino acid sequence of the dog prepro sequence upstream of the Ser residue to which R<sup>3</sup> is bound shown in Figure 8 herein or a C-terminal portion thereof;  
R<sup>2</sup> is OH, NH<sub>2</sub>, or NR<sub>2</sub> wherein each R is independently H or lower alkyl (1-4C) or R<sup>2</sup> is Asn;  
Asn-Val;  
Asn-Val-Leu;  
Asn-Val-Leu-Arg;  
Asn-Val-Leu-Arg-Lys; or  
Asn-Val-Leu-Arg-Lys-Tyr;  
or a C-terminal amide thereof.

38. The antibodies of claim 37 wherein said canine natriuretic peptide is Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Asn-Val-Leu-Arg-Lys-Tyr;  
or a C-terminal amide thereof.

39. The antibodies of claim 37 wherein the said canine natriuretic peptide R<sup>3</sup> is H and R<sup>2</sup> is OH or NH<sub>2</sub>.

40. The antibodies of claim 37 wherein the said canine natriuretic peptide R<sup>1</sup> is H and R<sup>2</sup> is OH or NH<sub>2</sub>.

41. The antibodies of claim 32 which are monoclonal antibodies.

42. The antibodies of claim 32 which further comprise a label.